Total Payments
$22,842
2024 Payments
$15,069
Companies
20
Transactions
72
Medicare Patients
1,272
Medicare Billing
$233,593
Payment Breakdown by Category
Consulting$15,540 (68.0%)
Travel$3,820 (16.7%)
Food & Beverage$2,093 (9.2%)
Research$1,132 (5.0%)
Education$256.94 (1.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $15,540 | 3 | 68.0% |
| Travel and Lodging | $3,820 | 11 | 16.7% |
| Food and Beverage | $2,093 | 48 | 9.2% |
| Unspecified | $1,132 | 7 | 5.0% |
| Education | $256.94 | 3 | 1.1% |
Payments by Type
General
$21,710
65 transactions
Research
$1,132
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADC Therapeutics America, Inc. | $11,034 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $5,906 | 23 | $0 (2024) |
| Kyowa Kirin, Inc. | $3,850 | 7 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $1,246 | 9 | $0 (2018) |
| Celgene Corporation | $196.68 | 5 | $0 (2018) |
| Kite Pharma, Inc. | $124.98 | 1 | $0 (2018) |
| Seattle Genetics, Inc. | $99.00 | 1 | $0 (2019) |
| Astellas Pharma US Inc | $78.76 | 2 | $0 (2018) |
| Takeda Pharmaceuticals U.S.A., Inc. | $44.43 | 2 | $0 (2024) |
| GENZYME CORPORATION | $39.66 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15,069 | 21 | ADC Therapeutics America, Inc. ($11,034) |
| 2023 | $37.40 | 1 | Genentech USA, Inc. ($37.40) |
| 2020 | $1,876 | 12 | AstraZeneca Pharmaceuticals LP ($1,876) |
| 2019 | $3,991 | 10 | Kyowa Kirin, Inc. ($3,850) |
| 2018 | $1,491 | 17 | Pharmacyclics LLC, An AbbVie Company ($1,146) |
| 2017 | $378.89 | 11 | Celgene Corporation ($145.21) |
All Payment Transactions
72 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $66.57 | General |
| 12/10/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $17.28 | General |
| 10/31/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $9,600.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $322.94 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $140.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $72.00 | General |
| 09/20/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $40.00 | General |
| 09/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $28.71 | General |
| Category: Oncology | ||||||
| 09/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | ADC Therapeutics America, Inc. | — | Travel and Lodging | Cash or cash equivalent | $675.46 | General |
| 08/24/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $16.75 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Oncology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | Cash or cash equivalent | $58.11 | General |
| Category: Oncology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | Cash or cash equivalent | $41.38 | General |
| Category: Oncology | ||||||
| 08/01/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,740.00 | General |
| Category: Oncology | ||||||
| 07/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $616.49 | General |
| Category: Oncology | ||||||
| 07/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $359.65 | General |
| Category: Oncology | ||||||
| 07/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $74.68 | General |
| Category: Oncology | ||||||
| 07/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: Oncology | ||||||
| 07/13/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $16.29 | General |
| Category: Oncology | ||||||
| 06/03/2023 | Genentech USA, Inc. | Lunsumio (Biological), Polivy | Food and Beverage | In-kind items and services | $37.40 | General |
| Category: BioOncology | ||||||
| 02/26/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $124.93 | General |
| Category: Oncology | ||||||
| 02/26/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $2.07 | General |
| Category: Oncology | ||||||
| 02/08/2020 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $154.10 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1143-CA | Pharmacyclics LLC, An AbbVie Company | $1,132 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 443 | 949 | $176,061 | $80,669 |
| 2022 | 6 | 351 | 749 | $152,181 | $70,265 |
| 2021 | 6 | 242 | 543 | $99,582 | $46,053 |
| 2020 | 8 | 236 | 526 | $97,845 | $36,605 |
Total Patients
1,272
Total Services
2,767
Medicare Billing
$233,593
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 116 | 447 | $98,904 | $47,632 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 110 | 162 | $21,825 | $11,549 | 52.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 92 | $24,472 | $8,561 | 35.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 115 | 163 | $9,153 | $5,995 | 65.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $15,695 | $4,972 | 31.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 25 | $4,625 | $1,547 | 33.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 17 | $1,387 | $413.44 | 29.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 122 | 390 | $87,126 | $44,152 | 50.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 102 | $27,132 | $8,204 | 30.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 59 | 85 | $11,975 | $6,228 | 52.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 90 | 127 | $7,560 | $4,984 | 65.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $11,680 | $4,656 | 39.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 12 | 13 | $6,708 | $2,040 | 30.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 216 | $48,204 | $24,014 | 49.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 101 | $14,119 | $6,986 | 49.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 77 | 135 | $7,875 | $5,345 | 67.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 57 | $15,162 | $4,614 | 30.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 22 | 22 | $8,030 | $3,212 | 40.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $6,192 | $1,883 | 30.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 44 | 147 | $32,604 | $12,268 | 37.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 19 | 143 | $38,038 | $11,855 | 31.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 49 | 81 | $11,322 | $4,926 | 43.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 26 | 26 | $9,490 | $3,384 | 35.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 45 | 59 | $3,186 | $2,335 | 73.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 19 | 25 | $1,675 | $1,085 | 64.8% |
About Abhijeet Kumar
Abhijeet Kumar is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2011. The National Provider Identifier (NPI) number assigned to this provider is 1134409923.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Abhijeet Kumar has received a total of $22,842 in payments from pharmaceutical and medical device companies, with $15,069 received in 2024. These payments were reported across 72 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($15,540).
As a Medicare-enrolled provider, Kumar has provided services to 1,272 Medicare beneficiaries, totaling 2,767 services with total Medicare billing of $233,593. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 08/24/2011
- Last Updated 10/05/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1134409923
Products in Payments
- CALQUENCE (Drug) $5,780
- POTELIGEO (Drug) $3,850
- Ibrutinib (Drug) $1,132
- Yescarta (Drug) $124.98
- Abraxane (Drug) $120.14
- Imbruvica (Drug) $114.35
- Revlimid (Drug) $76.54
- LYNPARZA (Drug) $46.28
- ZYTIGA (Drug) $38.16
- Lunsumio (Biological) $37.40
- SARCLISA (Biological) $28.71
- ELIQUIS (Drug) $27.07
- Venclexta (Drug) $21.71
- Cresemba (Drug) $20.81
- TALVEY (Biological) $20.51
- ALUNBRIG (Drug) $18.04
- Nplate (Biological) $16.83
- XTANDI (Drug) $16.75
- JAKAFI (Drug) $15.27
- FARYDAK (Drug) $15.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816